Kyverna Therapeutics Q3 2024 Update
Ticker: KYTX · Form: 10-Q · Filed: Nov 13, 2024 · CIK: 1994702
Sentiment: neutral
Topics: 10-Q, biotech, R&D expenses, licensing
Related Tickers: KYTX
TL;DR
Kyverna's Q3 2024 10-Q shows R&D spend and Kite licensing details. $KYTX
AI Summary
Kyverna Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the third quarter of 2024. It also disclosed details regarding its Kite License Agreement, including accrued license expenses from January 1, 2024, to September 30, 2024, with Kite Pharma, Inc. The filing also mentions shares available for future option grants as of December 31, 2023.
Why It Matters
This filing provides insight into Kyverna Therapeutics' operational expenses and licensing agreements, crucial for understanding its financial health and future development pipeline.
Risk Assessment
Risk Level: medium — Biotech companies often carry inherent risks due to the nature of drug development and regulatory approvals.
Key Numbers
- 2024-09-30 — Reporting Period End Date (Indicates the timeframe covered by the financial data.)
- 2024-01-01 to 2024-09-30 — Accrued License Expense Period (Covers the period for which license expenses were accrued under the Kite agreement.)
- 2023-12-31 — Shares Available for Future Option Grants Date (Snapshot of equity incentive availability.)
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Filer of the 10-Q
- September 30, 2024 (date) — End of reporting period
- Kite License Agreement (contract) — Key agreement mentioned
- Kite Pharma, Inc. (company) — Party to the license agreement
- December 31, 2023 (date) — Date for shares available for option grants
FAQ
What were Kyverna Therapeutics' research and development expenses for the third quarter of 2024?
The filing indicates research and development expenses were incurred for the period of July 1, 2024, to September 30, 2024.
What is the nature of the relationship between Kyverna Therapeutics and Kite Pharma, Inc. as detailed in this filing?
The filing mentions a Kite License Agreement between Kyverna Therapeutics and Kite Pharma, Inc., with accrued license expenses noted for the period January 1, 2024, to September 30, 2024.
What information is provided regarding Kyverna's equity incentive plans?
The filing specifies the number of shares available for future option grants as of December 31, 2023.
What is the fiscal year end for Kyverna Therapeutics?
Kyverna Therapeutics' fiscal year ends on December 31.
When was this 10-Q filing submitted?
This 10-Q filing was submitted on November 13, 2024.
Filing Stats: 4,475 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2024-11-13 16:24:17
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share KYTX The Nasdaq Stock Mar
Filing Documents
- kytx-20240930.htm (10-Q) — 2566KB
- kytx-ex31_1.htm (EX-31.1) — 15KB
- kytx-ex31_2.htm (EX-31.2) — 15KB
- kytx-ex32_1.htm (EX-32.1) — 11KB
- kytx-ex32_2.htm (EX-32.2) — 10KB
- 0000950170-24-126366.txt ( ) — 8740KB
- kytx-20240930.xsd (EX-101.SCH) — 1083KB
- kytx-20240930_htm.xml (XML) — 1354KB
Financial Statements (Unaudited)
Financial Statements (Unaudited) 1 Condensed Balance Sheets 1 Condensed Statements of Operations and Comprehensive Income (Loss) 2 Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) 3 Condensed Statements of Cash Flows 4 Notes to Condensed Financial Statements 5 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.
Controls and Procedures
Controls and Procedures 31 PART II. OTHER INFORMATION 33 Item 1.
Legal Proceedings
Legal Proceedings 33 Item 1A.
Risk Factors
Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 90 Item 3. Defaults Upon Senior Securities 90 Item 4. Mine Safety Disclosures 90 Item 5. Other Information 91 Item 6. Exhibits 91
—FIN ANCIAL INFORMATION
PART I—FIN ANCIAL INFORMATION Ite m 1. Financial Statements (unaudited) Kyverna Therapeutics, Inc. Con densed Balance Sheets (in thousands, except share and per share data) (unaudited) September 30, December 31, 2024 2023 Assets Current assets Cash and cash equivalents $ 104,663 $ 34,647 Available-for-sale marketable securities 216,924 22,896 Prepaid expenses and other current assets 3,787 3,121 Total current assets 325,374 60,664 Restricted cash 564 565 Property and equipment, net 3,151 2,326 Operating lease right-of-use assets 7,153 6,494 Finance lease right-of-use assets 1,078 1,790 Other non-current assets 1,876 3,356 Total assets $ 339,196 $ 75,195 Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) Current liabilities Accounts payable $ 9,932 $ 4,358 Accrued compensation 4,440 2,812 Accrued license expense – related party 6,250 6,250 Other accrued expenses and current liabilities 6,432 3,519 Operating lease liabilities, short-term portion 3,000 1,964 Finance lease liabilities, short-term portion 931 956 Total current liabilities 30,985 19,859 Operating lease liabilities, net of short-term portion 4,968 5,238 Finance lease liabilities, net of short-term portion 237 921 Other non-current liabilities 296 — Total liabilities 36,486 26,018 Commitments and contingencies (Note 7) Redeemable convertible preferred stock, no par value no shares authorized, issued and outstanding as of September 30, 2024 $ 0.00001 par value, 114,556,997 shares authorized as of December 31, 2023; 114,556,997 shares issued and outstanding as of December 31, 2023; liquidation preference of $ 181,273 as of December 31, 2023 — 180,574 Stockholders' equity (deficit) Preferred stock, 10,000,000 shares authorized, $ 0.00001 par value, no shares issued and outstanding as of September 30, 2